<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="1832">
  <stage>Registered</stage>
  <submitdate>3/01/2008</submitdate>
  <approvaldate>3/01/2008</approvaldate>
  <nctid>NCT00622089</nctid>
  <trial_identification>
    <studytitle>Open Label Safety &amp; Pharmacodynamic Study 24Wk w/DIO-902 Combo w/Metformin &amp; Atorvastatin in T2DM Patients</studytitle>
    <scientifictitle>An Open Label Follow-On Study of Safety and Pharmacodynamic Effects of 24 Weeks of Treatment With DIO-902 in Combination With Metformin and Atorvastatin in Subjects With Type 2 Diabetes Mellitus (Protocol No. DIO-503)</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>DIO-503</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Type 2 Diabetes</healthcondition>
    <conditioncode>
      <conditioncode1>Metabolic and Endocrine</conditioncode1>
      <conditioncode2>Diabetes</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - DIO-902
Treatment: drugs - DIO-902
Treatment: drugs - DIO-902

Experimental: 1 - 150mg DIO-902 + 10mg Atorvastatin

Experimental: 2. - 300mg DIO-902 + 10mg Atorvastatin

Experimental: 3 - 450mg DIO-902 + 10mg Atorvastatin


Treatment: drugs: DIO-902
150mg DIO-902 + 10mg atorvastatin

Treatment: drugs: DIO-902
300mg dose once per day for 24 weeks

Treatment: drugs: DIO-902
450mg dose once per day for 24 weeks

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>The following parameters will be evaluated at Week 12 and Week 24:  Proportion of subjects who reach the lipid goal as defined in the protocol from baseline  Proportion of subjects who meet the HbA1c goal as defined in the protocol from baseline</outcome>
      <timepoint>24 weeks</timepoint>
    </primaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Participated in DIO-502</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>75</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Did not participate in DIO-502</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2/Phase 3</phase>
    <anticipatedstartdate />
    <actualstartdate>1/01/2008</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>150</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Terminated</recruitmentstatus>
    <anticipatedlastvisitdate>1/12/2008</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>SA,VIC,WA</recruitmentstate>
    <hospital>Flinders Medical Centre - Adelaide</hospital>
    <hospital>Lyell McEwin Hospital - North Western Adelaide</hospital>
    <hospital>ECRU - Box Hill, Melbourne</hospital>
    <hospital>School of Medicine and Pharmacology - Fremantle</hospital>
    <hospital>Keough Institute - Nedands</hospital>
    <hospital>Endocrinology Research Unit - Herston Road</hospital>
    <hospital>Endocrinology Department - St Leonards</hospital>
    <hospital>Royal Melbourn Hospital - Victoria</hospital>
    <postcode> - Adelaide</postcode>
    <postcode> - North Western Adelaide</postcode>
    <postcode> - Box Hill, Melbourne</postcode>
    <postcode>6160 - Fremantle</postcode>
    <postcode>6009 - Nedands</postcode>
    <postcode>QLD 4029 - Herston Road</postcode>
    <postcode>NSW 2065 - St Leonards</postcode>
    <postcode> - Victoria</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Alabama</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Arizona</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Arkansas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>California</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Hawaii</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Nebraska</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Oklahoma</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Oregon</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Texas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Auckland</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Christchurch</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Hamilton</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Wellington</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>DiObex</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>DiObex Inc. is developing an experimental drug (DIO-902) that is made up of part of the
      ketoconazole molecule for the treatment of elevated blood glucose associated with type 2
      diabetes mellitus. Ketoconazole (NizoralÂ®) is a drug available by prescription for the
      treatment of fungal infections however DIO-902 is an investigational drug. DIO-902 may lower
      blood glucose by lowering levels of a naturally occurring hormone called cortisol. Elevated
      cortisol may contribute to the development of type 2 diabetes.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00622089</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>